Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 150 Results

Title
Intervention Indication Therapeutic Area Year Actions
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma Pirtobrutinib (LY3527727; LOXO-305) Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL) Haematological Cancer and Lymphomas 2023 View  |  Download
Polatuzumab vedotin in addition to R-CHP for diffuse large B-cell lymphoma – first line Chemotherapy , Polatuzumab vedotin (DCDS4501A; RG7596; RG-7596; Polivy) Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2020 View  |  Download
Polatuzumab vedotin in combination with rituximab and bendamustine for the treatment of diffuse large B-cell lymphoma Bendamustine (Treanda; EP-3102; Levact; Ribomustin; bendamustine hydrochloride monohydrate; bendamustine hydrochloride) , Polatuzumab vedotin (DCDS4501A; RG7596; RG-7596; Polivy) , Rituximab (MabThera; Rituxan; RG 105) Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2018 View  |  Download
Pomalidomide (Imnovid) with bortezomib and dexamethasone for relapsed or refractory multiple myeloma‐ second line and beyond Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Pomalidomide (Imnovid; CC-4047; Pomalyst) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2017 View  |  Download
Quizartinib with chemotherapy for FLT3-ITD positive acute myeloid leukaemia Quizartinib (AC220) Acute myeloid leukaemia (AML) Haematological Cancer and Lymphomas 2021 View  |  Download
REGN5458 for relapsed or refractory multiple myeloma REGN5458 Multiple myeloma (MM) Haematological Cancer and Lymphomas 2022 View  |  Download
Rigosertib for myelodysplastic syndrome - second line Rigosertib (Estybon; ON-01910.Na) Myelodysplastic syndrome (MDS) Haematological Cancer and Lymphomas 2020 View  |  Download
Ropeginterferon alfa-2b for polycythaemia vera without symptomatic splenomegaly Ropeginterferon alfa 2-b (P-1101; AOP2014; Pegylated-Proline-interferon alpha-2b) Polycythaemia vera Haematological Cancer and Lymphomas 2019 View  |  Download
Sabatolimab in addition to azacitidine for myelodysplastic syndromes – first-line Azacitidine (Vidaza; CC-486) , Sabatolimab (MBG453) Chronic myelomonocytic leukaemia (CMML) , Myelodysplastic syndrome (MDS) Haematological Cancer and Lymphomas 2021 View  |  Download
Selinexor in addition to bortezomib and low-dose dexamethasone for relapsed or refractory multiple myeloma Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Selinexor (KPT-330; Xpovio) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2020 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications